EP Vantage is a forward-looking comment and analysis service tailored to the needs of pharma and finance professionals, focusing on the events that will define the future of companies, products and therapy areas. Written by experienced journalists, EP Vantage provides timely financial analysis of regulatory and patent decisions, marketing approvals, licensing deals, and M&A, giving fresh angles and insight to both current and future industry triggers. EP Vantage is powered by EvaluatePharma, the industry leader in consensus forecasts.
My professional experience is in private energy sector:
10+ years experience: Market risk controlling within a leading European Energy commodity trading company – Executive
8 years experience: investment appraisal and profitability analysis within a major European Energy company - Analyst
Masters mechanical /industrial engineer and applied economic
20+ years experience in equity investments.
My strategy and investment horizon will mostly be mid (3-6 month) to long term (>6 month) rather than short term trading.
Investment region mainly is Europe and North/South America.
As investor I will base my investment decisions primarily on fundamental analysis, which is supported by technical analysis for identifying entry and exit points. I apply a strict money management system on my positions.
Investor in dividend stocks with a promising future ;-)
ABT, ADM, BBZ, BDX, CSCO, D, DE, FLO, GE, GIS, GPC, HASI, HD, HRL, IBM, JCI, JNJ, KHC, KO, LMT, MSEX, MSFT, MMM, MO, OHI, PAYX, PEP, PFE, PG, SO, QCOM,T, TGT, THW, UN, WMT, WTR